Abstract #0089

Gd-Staining Reveals the Efficacy of an Anti-A&[beta] Antibody to Decrease Amyloid Plaque Load in Vivo in a Transgenic Mouse Model of Alzheimer's Disease

Mathieu David Santin¹,², Thomas Debeir³, Thierry Delzescaux²,⁴, Anne-Sophie Herard²,⁴, Caroline Cohen³, Laurent Pradier³, Thomas Rooney³, Marc Dhenain²,⁴

¹Centre de Neuroimagerie de Recherche CENIR, Institut du Cerveau et de la Moelle pinire ICM, Paris, France; ²URA 2210 CEA/CNRS, Fontenay-aux-Roses, France; ³Therapeutic Strategy Unit Aging, Sanofi, Chilly-Mazarin, France; ⁴MIRCen, CEA / I2BM, Fontenay-aux-Roses, France

This work describes the use of Gd-Staining MRI to quantify the efficacy of an immunotherapy in a mouse model of cerebral amyloidosis. We showed that this technique is suitable for longitudinal studies and provided age-associated increase of amyloid plaques in transgenic mice.